Stifel on Xenon Pharmaceuticals (XENE): 'We continue to believe >$2B US peak sales in FOS is very realistic'

April 20, 2026 6:31 AM

Stifel on Xenon Pharmaceuticals (NASDAQ: XENE): 'We continue to believe >$2B US peak sales in FOS is very realistic'.The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found